These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35673029)

  • 1. Detecting Drug-Drug Interactions in COVID-19 Patients.
    Jeong E; Person AK; Stollings JL; Su Y; Li L; Chen Y
    Stud Health Technol Inform; 2022 Jun; 290():330-334. PubMed ID: 35673029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System.
    Wang X; Li L; Wang L; Feng W; Zhang P
    Stat Med; 2020 Mar; 39(7):996-1010. PubMed ID: 31880829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review.
    Conti V; Sellitto C; Torsiello M; Manzo V; De Bellis E; Stefanelli B; Bertini N; Costantino M; Maci C; Raschi E; Sabbatino F; Corbi G; Pagliano P; Filippelli A
    JAMA Netw Open; 2022 Apr; 5(4):e227970. PubMed ID: 35438752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system.
    Jeong E; Nelson SD; Su Y; Malin B; Li L; Chen Y
    Front Pharmacol; 2022; 13():938552. PubMed ID: 35935872
    [No Abstract]   [Full Text] [Related]  

  • 5. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
    Preskorn SH; Quadri S
    J Psychiatr Pract; 2020 Nov; 26(6):485-492. PubMed ID: 33275385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach.
    Wang L; Shendre A; Chiang CW; Cao W; Ning X; Zhang P; Zhang P; Li L
    Br J Clin Pharmacol; 2022 Feb; 88(4):1471-1481. PubMed ID: 33543792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mining and visualizing high-order directional drug interaction effects using the FAERS database.
    Yao X; Tsang T; Sun Q; Quinney S; Zhang P; Ning X; Li L; Shen L
    BMC Med Inform Decis Mak; 2020 Mar; 20(Suppl 2):50. PubMed ID: 32183790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.
    Leone R; Magro L; Moretti U; Cutroneo P; Moschini M; Motola D; Tuccori M; Conforti A
    Drug Saf; 2010 Aug; 33(8):667-75. PubMed ID: 20635825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions.
    Crescioli G; Brilli V; Lanzi C; Burgalassi A; Ieri A; Bonaiuti R; Romano E; Innocenti R; Mannaioni G; Vannacci A; Lombardi N
    Intern Emerg Med; 2021 Apr; 16(3):697-710. PubMed ID: 33355896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-driven prediction of adverse drug reactions induced by drug-drug interactions.
    Liu R; AbdulHameed MDM; Kumar K; Yu X; Wallqvist A; Reifman J
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):44. PubMed ID: 28595649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items.
    Kovačević M; Vezmar Kovačević S; Radovanović S; Stevanović P; Miljković B
    Curr Med Res Opin; 2019 Nov; 35(11):1873-1883. PubMed ID: 31328967
    [No Abstract]   [Full Text] [Related]  

  • 12. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
    Xu R; Wang Q
    J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-year retrospective study of adverse drug reactions due to drug-drug interactions between nervous system drugs.
    Shi QP; He XD; Yu ML; Zhu JX; Liu Y; Ding F; Sang R; Jiang XD; Zhang SQ
    Int J Clin Pharmacol Ther; 2014 May; 52(5):392-401. PubMed ID: 24691061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system.
    Toivo TM; Mikkola JA; Laine K; Airaksinen M
    Res Social Adm Pharm; 2016; 12(4):559-68. PubMed ID: 26459026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital.
    Ramasubbu SK; Mahato SK; Agnihotri A; Pasricha RK; Nath UK; Das B
    Cancer Treat Res Commun; 2021; 26():100277. PubMed ID: 33348276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
    Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
    Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.
    Dechanont S; Maphanta S; Butthum B; Kongkaew C
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):489-97. PubMed ID: 24616171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
    González-Colominas E; Londoño MC; Morillas RM; Torras X; Mojal S; Lens S; López D; Gallego A; Mariño Z; Ardèvol M; Pagès N; Solà R; Carrión JA
    J Gastroenterol Hepatol; 2018 May; 33(5):1100-1107. PubMed ID: 28994141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixture drug-count response model for the high-dimensional drug combinatory effect on myopathy.
    Wang X; Zhang P; Chiang CW; Wu H; Shen L; Ning X; Zeng D; Wang L; Quinney SK; Feng W; Li L
    Stat Med; 2018 Feb; 37(4):673-686. PubMed ID: 29171062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.